Tirofiban Hydrochloride Injection
Product Images NDC 14789-101

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tirofiban Hydrochloride (NDC 14789-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nexus Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Tir00 0010 01)

A chemical structure diagram depicting the molecular formula and arrangement of Tirofiban Hydrochloride, an active pharmaceutical ingredient. The structure shows atoms and bonds typical of a small molecule drug used in intravenous injection formulations.*

FDA Label Image

Figure (Tir00 0010 02)

A mathematical formula calculating the infusion rate for Tirofiban Hydrochloride injection in patients with creatinine clearance greater than 60 mL/min. The formula involves dosage weight, body weight in kilograms, and conversion factors to determine the infusion rate in mL/h.*

FDA Label Image

Figure (Tir00 0010 03)

A line chart titled "Infusion Rate for CrCl > 60 mL/min" shows infusion rate calculations for Tirofiban Hydrochloride injection, illustrating the relationship between the infusion rate (mL/h) and patient parameters. The graph includes a calculation formula for a patient weighing 60 kg, resulting in an infusion rate of 10.8 mL/h.*

FDA Label Image

Figure (Tir00 0010 04)

A partial text panel showing a formula for calculating the infusion rate of Tirofiban Hydrochloride injection for patients with creatinine clearance (CrCl) of 60 mL/min or less. The formula involves dosage in mcg/kg/min, body weight in kg, and a concentration of 50 mcg/mL.*

FDA Label Image

Figure (Tir00 0010 05)

Chemical structure of Tirofiban Hydrochloride shown as a detailed molecular diagram including functional groups and associated molecules such as hydrochloride and water.*

FDA Label Image

Figure 1 (Tir00 0010 06)

A line graph titled 'Composite Endpoint 180-day Follow-up' comparing the proportion with endpoint over time between Heparin alone and Tirofiban Hydrochloride Injection plus Heparin. The x-axis represents study days (0 to 180) and the y-axis shows the proportion with endpoint (0.00 to 0.35). The graph highlights a 22% risk reduction (p=0.029) early in the study and a 19% risk reduction (p=0.024) at day 180 for the combination treatment versus Heparin alone.*

FDA Label Image

Principal Display Panel – 100 mL Carton Label (Tir00 0010 07)

Packaging label of Tirofiban Hydrochloride Injection, 50 mcg/mL (5 mg per 100 mL) premixed intravenous injection in a 100 mL single-dose container by Nexus Pharmaceuticals LLC. The label includes storage instructions, warnings, and manufacturer information.*

FDA Label Image

Principal Display Panel – 100 mL Bag Label (Tir00 0010 08)

Label for Tirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL) in a 100 mL single-dose container for intravenous use. The label notes it is pre-mixed, iso-osmotic, sterile, and non-pyrogenic. Manufactured for Nexus Pharmaceutical, Inc., the label includes storage recommendations and cautions against adding supplementary medication or using the solution if not clear.*

FDA Label Image

Principal Display Panel – 250 mL Carton Label (Tir00 0010 09)

The packaging label for Tirofiban Hydrochloride Injection, 12.5 mg per 250 mL (50 mcg per mL), in a 250 mL single-dose container for intravenous use. The label includes storage instructions, cautions, and manufacturer information for Nexus Pharmaceuticals LLC, located in Lincolnshire, IL. The label design features an orange band with the drug name and concentration prominently displayed.*

FDA Label Image

Principal Display Panel – 250 mL Bag Label (Tir00 0010 10)

Label for Tirofiban Hydrochloride Injection 50 mcg/mL (12.5 mg/250 mL) in a 250 mL single-dose container. The injection is pre-mixed, iso-osmotic, sterile, and non-pyrogenic. Manufactured for Nexus Pharmaceuticals LLC. The label includes storage recommendations, cautions, and a barcode along with a space for lot and expiration information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.